Ideal Medical Technologies
Ideal Medical Technologies focuses on developing artificially intelligent, hospital-based closed-loop control systems for critical care settings, specifically for glucose management. Their primary product is a closed-loop glucose control platform designed to autonomously regulate intravenous insulin and dextrose infusions in ICU and non-ICU settings, reducing the burden on nursing staff while improving clinical outcomes. The company actively pursues rigorous clinical validation, regulatory compliance, and has been recognized with Breakthrough Medical Device designation.
Industries
N/A
Ideal Medical Technologies
45 S. French Broad Avenue, Suite 145, Asheville, NC 28801
Patents
Products
A hospital-based, AI-driven platform designed to autonomously manage intravenous insulin and dextrose infusions for glucose control in critical care settings, minimizing nurse workload and reducing human error.
A hospital-based, AI-driven platform designed to autonomously manage intravenous insulin and dextrose infusions for glucose control in critical care settings, minimizing nurse workload and reducing human error.
Expertise Areas
- Closed-loop glucose management
- Artificial intelligence in critical care
- Clinical trial execution for medical devices
- Regulatory compliance for health technology
Key Technologies
- Artificial intelligence
- Closed-loop control systems
- Continuous glucose monitoring
- Clinical data analytics
Key People
Founder, Chief Executive Officer
Chief Technology Officer
Founder, Chief Executive Officer
Chief Technology Officer
News & Updates
Received FDA Breakthrough Medical Device designation for the closed-loop glucose control system, facilitating prioritized regulatory feedback.
Completed first-in-human safety study demonstrating high efficacy and safety for closed-loop glucose control, presented at the 2023 ADA meeting.
Received $1.9M funding from the NIH for the ongoing development and clinical study of the closed-loop glucose control system.
Simulation study comparing AI-driven glucose control software to existing ICU control systems, with significant performance advantages.
The FDA approved a new IDE application enabling further clinical trials of the closed-loop glucose control system, confirming the application's completeness and alignment with current FDA guidance for medical device software.
IMT was chosen to present at the NC MedTech Venture Day forum and BioFuture 2024 investors meeting.
Received FDA Breakthrough Medical Device designation for the closed-loop glucose control system, facilitating prioritized regulatory feedback.
Completed first-in-human safety study demonstrating high efficacy and safety for closed-loop glucose control, presented at the 2023 ADA meeting.
Received $1.9M funding from the NIH for the ongoing development and clinical study of the closed-loop glucose control system.
Simulation study comparing AI-driven glucose control software to existing ICU control systems, with significant performance advantages.
The FDA approved a new IDE application enabling further clinical trials of the closed-loop glucose control system, confirming the application's completeness and alignment with current FDA guidance for medical device software.
IMT was chosen to present at the NC MedTech Venture Day forum and BioFuture 2024 investors meeting.